CLVLY Clinuvel Pharms Ltd S/Adr

22.98
-0.97  -4%
Previous Close 23.95
Open 22.95
Price To Book 29.46
Market Cap 1,125,115,346
Shares 48,960,633
Volume 36,757
Short Ratio
Av. Daily Volume 14,607
Stock charts supplied by TradingView

NewsSee all news

  1. FDA Approves SCENESSE® For Genetic Disorder

    MELBOURNE, Australia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has approved a new drug as the first ever treatment for a rare genetic metabolic disorder which causes absolute

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced October 8, 2019.
SCENESSE
Phototoxicity and anaphylactoid reactions in adult patients with erythropoietic protoporphyria (EPP)

Latest News

  1. FDA Approves SCENESSE® For Genetic Disorder

    MELBOURNE, Australia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has approved a new drug as the first ever treatment for a rare genetic metabolic disorder which causes absolute